From the Editor-in-Chief The Tumor Microenvironment Research is leading to treatments that target cancer’s support system. by William G. Nelson, MD, PhD Forward Look First CAR-T Cell Therapy Approved for Multiple Myeloma Cellular immunotherapies can offer periods when people do not require treatment. by Christina Bennett Forward Look Going Flat Most people who opt out of breast reconstruction are satisfied with their decision but are not always supported by their surgeons. by Kris Conner Forward Look What’s Next? Using fecal transplants to improve immunotherapy response by Natalie Slivinski Are You a Candidate for Immunotherapy? Tumor testing can help determine whether certain cancers are likely to respond to immunotherapy drugs. by Kendall K. Morgan A Fast Track for Cancer Vaccines The rapid development of mRNA COVID-19 vaccines could spark advances in similar treatments for cancer. by Stephen Ornes A Treatment That Came Just in Time Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma. by Laurie Adami Genetic Testing Gaps Testing for hereditary mutations is increasingly recommended for people with cancer, but recommendations do not always translate into access to testing and appropriate counseling. by Kate Yandell Expanding Immunotherapy At a patient advocate event, researchers discussed how to extend the benefits of immunotherapy to more people. by Kevin McLaughlin Should All Kids With Cancer Get Genetic Testing? Testing children with cancer for hereditary mutations could impact their treatment and provide information relevant to other family members. by Marcus A. Banks next Cancer Talk Drug Delays Recurrence in People With Early-Stage Breast Cancer People who have inherited BRCA mutations and are at high risk for cancer recurrence may benefit from a PARP inhibitor. by Pamela Rafalow Grossman Open Medical Records: Pros and Cons Patients now have full access to their online medical records. What are the benefits and downsides? by Jen Tota McGivney Remote Care After adapting remote patient monitoring programs to cancer patients with COVID-19, cancer centers delve deeper into the programs’ value for cancer patients undergoing treatment. by Jon Kelvey Moving Away From the Maximum Tolerated Dose The FDA recently expressed a new commitment to testing cancer drugs at lower doses, rather than defaulting to the highest dose most people can tolerate. by Marcus A. Banks More Posts